This work is supported by the Emory-Georgia Tech CCNE consortium, Georgia Cancer Coalition (S.N. and R.M.O.R GCC Distinguished Scholars), and NSF (X.H.G. NSF-CAREER award). We are also grateful to Prof. Larry True (UW Pathology) for fruitful discussion.
In Situ Molecular Profiling of Breast Cancer Biomarkers with Multicolor Quantum Dots†
Article first published online: 17 OCT 2007
Copyright © 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Special Issue: Special Section on Bionanotechnology
Volume 19, Issue 20, pages 3146–3151, October, 2007
How to Cite
Yezhelyev, M. V., Al-Hajj, A., Morris, C., Marcus, A. I., Liu, T., Lewis, M., Cohen, C., Zrazhevskiy, P., Simons, J. W., Rogatko, A., Nie, S., Gao, X. and O'Regan, R. M. (2007), In Situ Molecular Profiling of Breast Cancer Biomarkers with Multicolor Quantum Dots. Adv. Mater., 19: 3146–3151. doi: 10.1002/adma.200701983
- Issue published online: 17 OCT 2007
- Article first published online: 17 OCT 2007
- Manuscript Received: 3 AUG 2007
- Emory-Georgia Tech CCNE consortium
- Georgia Cancer Coalition
- Biomedical materials;
- Quantum dots
Quantum dot bioconjugates can be used for multiplexed and quantitative detection of tumor biomarkers in cells and tissues. This new technology should have significant impact on molecular pathology if validated with traditional techniques (such as western blotting, FISH, and IHC), and with large-scale clinical studies. In addition, it could also become the first clinical application of quantum dots.